Back to Feed
Stem cell research & therapy|Peer-Reviewed
Mesenchymal stem cell derived exosomes mitigate COVID-19 cytokine storm via Annexin A1 and TGF-β mediated MAPK pathway inhibition.
Nesrine Ebrahim, Hajir A Al Saihati, Arigue A Dessouky, Yasmeen Mohammed Ismail, Ashraf A Shamaa, Shereen A Mohamed, Mohamed E Mohamed, Nermine Nosseir, Mohamed Ahmed Eladl, Gianpiero Di Leva, Omnia A Badr
Abstract
Severe COVID-19 is marked by a dysregulated inflammatory response, known as a cytokine storm, resulting in acute respiratory distress syndrome (ARDS) and multiple organ failure. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated potential as immunomodulatory agents. This work investigates the possibility of MSC-Exos to mitigate excessive inflammation in COVID-19 by targeting the mitogen-activated protein kinase (MAPK) signalling pathway.
Keywords
<Keyword MajorTopicYN="N">Cytokine modulationMAPK inhibitionSARS-CoV-2Small extracellular vesiclesTGF-beta signalingWharton’s jelly